Hepatitis News : Abbott’s Interferon-Free Hep C Regimen Boasts Over 90% Cure Rates
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis News » November 2012


emailprint

November 13, 2012

Abbott’s Interferon-Free Hep C Regimen Boasts Over 90% Cure Rates

The future of hepatitis C treatment was looking bright at the annual meeting of the American Association of the Study of Liver Disease (AASLD) in Boston as pharmaceutical and biotech companies lifted the curtain on a panoply of results from their hep C pipeline research. As Reuters reports, among the most exciting results were the high cure rates from Abbott Laboratories’ three-drug regimen in development, which led to a sustained virological response in 93 percent of people with hepatitis C virus (HCV) who had failed a previous treatment and 97 percent of treatment-naive patients.

Abbott’s interferon-free regimen includes a protease inhibitor known as ABT-450, a polymerase inhibitor called ABT-333, and an NS5A inhibitor, ABT-267. The drugs were studied both with and without ribavirin among people with genotype 1 infections—the most difficult to treat strain, and the most common. The top cure rates were found in the ribavirin-inclusive regimen, although even without that antiviral drug the trio cured 87 percent of treatment-naive patients. All cures were achieved in only 12 weeks, and just 4 out of the 448 participants left the study because of adverse events. This suggests these drugs are highly tolerable—which is especially notable considering the flu-like symptoms common in the interferon-based regimens that are the standard of treatment today.

To read the Reuters story, click here.

Search: Hepatitis C, HCV, virus, Abbott, regimen, 90 percent, cure, SVR, sustained virologic response, American Association of the Study of Liver Disease, Boston, hep C, ABT-33, ABT-450, polymerase inhibitor, ribavirin, Interferon-free, NS5A inhibitor, genotype 1, protease inhibitor


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Have you ever experienced digestive troubles while on hep C treatment?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.